1Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol, 2005,17(1):1.
2Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. Biol Chem, 2004, 279(18):19008.
3Henault M, Lee LN, Evans GF et al. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. Immunol Methods, 2005, 300 (1-2) : 93.
4Leadbetter EA, Rifkin IR, Hohlbaum AM et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature, 2002, 416 (6881) :603.
5Viglianti GA, Lau CM, Hanley TM et al. Activation of autoreactive b cells by CpG dsDNA. Immunity, 2003, ]9 (6) :837.
6Jegerlehner A, Maurer P, Bessa Jet al. TLR9 signaling in B cells determines class switch recombination :o IgG2a. Immunol, 2007, 178(4):2415.
7Christensen SR, Shupe Jet al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity, 2006, 25(3):417.
8Wu X, Peng S L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum, 2006, 54 ( 1 ) : 336.
9Christensen SR, Shlomchik M J. Regulation of lupus-related autoantibody production and clinical disease by Toll- like receptors. Semin Immunol, 2007, 19(1) : 11.
10Lartigue A, Courville P et al. Role of TLR9 in antinu-cleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. Immunol, 2006, 177(2) : 1349.
